- Zacks
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
- Zacks
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
- Investor's Business Daily
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
